Eleanor Brooks
@eleanorbrooks.bsky.social
Senior Lecturer in European Health Policy at University of Edinburgh. Research on regulatory management, impact assessment, Better Regulation, fiscal governance, and the intersection of the above with (EU) health policy.
Reposted by Eleanor Brooks
Clean Industrial Deal risks becoming yet another example of corporate capture.
Without strong transparency rules & enforcement, plus real accountability, industry will continue to write the EU’s agenda behind closed doors.
✊ We need #lobbyingfirewall to protect public interest decision-making!
Without strong transparency rules & enforcement, plus real accountability, industry will continue to write the EU’s agenda behind closed doors.
✊ We need #lobbyingfirewall to protect public interest decision-making!
February 24, 2025 at 7:20 AM
Clean Industrial Deal risks becoming yet another example of corporate capture.
Without strong transparency rules & enforcement, plus real accountability, industry will continue to write the EU’s agenda behind closed doors.
✊ We need #lobbyingfirewall to protect public interest decision-making!
Without strong transparency rules & enforcement, plus real accountability, industry will continue to write the EU’s agenda behind closed doors.
✊ We need #lobbyingfirewall to protect public interest decision-making!
Commission's review of the #EuropesBeatingCancerPlan #EBCP cites 'current lack of evidence to suggest that further measures would add to the protection of EU citizens', beyond what's in the existing Low Voltage Directive commission.europa.eu/document/dow...
commission.europa.eu
February 5, 2025 at 8:11 AM
Commission's review of the #EuropesBeatingCancerPlan #EBCP cites 'current lack of evidence to suggest that further measures would add to the protection of EU citizens', beyond what's in the existing Low Voltage Directive commission.europa.eu/document/dow...
So one of the most important pieces of health legislation of this mandate, with implications for patients, pharmaceutical companies and health systems, will be proposed and adopted with no impact assessment or genuine public consultation, and little indication of why. #BetterRegulation...? /end
February 2, 2025 at 2:15 PM
So one of the most important pieces of health legislation of this mandate, with implications for patients, pharmaceutical companies and health systems, will be proposed and adopted with no impact assessment or genuine public consultation, and little indication of why. #BetterRegulation...? /end
Both the Political Guidelines for 2024-2029 (p.9) and the mission letter to the Health Commissioner (p.6) include a 100-day deadline for a proposal on Cyber Security for Hospitals & Healthcare Providers (announced 15 Jan), but no deadline for the Critical Medicines Act 8/9
February 2, 2025 at 2:15 PM
Both the Political Guidelines for 2024-2029 (p.9) and the mission letter to the Health Commissioner (p.6) include a 100-day deadline for a proposal on Cyber Security for Hospitals & Healthcare Providers (announced 15 Jan), but no deadline for the Critical Medicines Act 8/9
One justification being given is that the #CriticalMedicinesAct is meant to be proposed (the next stage) within the first 100 days of the new Commission, which are up at the beginning of March. But this is also strange because this deadline isn't mentioned anywhere in the Commission's plans... 7/9
February 2, 2025 at 2:15 PM
One justification being given is that the #CriticalMedicinesAct is meant to be proposed (the next stage) within the first 100 days of the new Commission, which are up at the beginning of March. But this is also strange because this deadline isn't mentioned anywhere in the Commission's plans... 7/9
...it also applies to 'medicines of common interest', a concept not clearly defined in the documentation but seeming to detract from the 'urgency' argument ec.europa.eu/info/law/bet... 6/9
European Commission - Have your say
European Commission - Have your say
ec.europa.eu
February 2, 2025 at 2:15 PM
...it also applies to 'medicines of common interest', a concept not clearly defined in the documentation but seeming to detract from the 'urgency' argument ec.europa.eu/info/law/bet... 6/9
The call for evidence lays out the problem - supply chains are vulnerable, shortages happen - but doesn't give concrete examples of life-threatening situations (I'm sure they exist, they're just not described). It's also worth noting that the act will be about more than just 'critical' drugs...5/9
February 2, 2025 at 2:15 PM
The call for evidence lays out the problem - supply chains are vulnerable, shortages happen - but doesn't give concrete examples of life-threatening situations (I'm sure they exist, they're just not described). It's also worth noting that the act will be about more than just 'critical' drugs...5/9
It's annoyingly hard to identify which Commission proposals are announced without impact assessments (I've found no centralised list for this) but known examples relate to the migration crisis and COVID-19 legislation (see SWD accomp. COM(2019)178, p.20). Is the CMA urgent in the same sense? 4/9
February 2, 2025 at 2:15 PM
It's annoyingly hard to identify which Commission proposals are announced without impact assessments (I've found no centralised list for this) but known examples relate to the migration crisis and COVID-19 legislation (see SWD accomp. COM(2019)178, p.20). Is the CMA urgent in the same sense? 4/9
On the 'urgency' exemption: the Commission's own rules say that impact assessment should be conducted for all initiatives 'expected to have significant economic, social or environmental impacts'. The Commission can itself exempt a proposal, and the language here is about urgency and security 3/9
February 2, 2025 at 2:15 PM
On the 'urgency' exemption: the Commission's own rules say that impact assessment should be conducted for all initiatives 'expected to have significant economic, social or environmental impacts'. The Commission can itself exempt a proposal, and the language here is about urgency and security 3/9
*given that the Council's upcoming agenda foresees adoption of the initiative by the Commission by 11 March, and the call for evidence (the only avenue for public consultation) closes on 27 February, it's hard to see how the input of stakeholders can be fully considered prior to drafting 2/9
February 2, 2025 at 2:15 PM
*given that the Council's upcoming agenda foresees adoption of the initiative by the Commission by 11 March, and the call for evidence (the only avenue for public consultation) closes on 27 February, it's hard to see how the input of stakeholders can be fully considered prior to drafting 2/9